Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
14 août 2024 16h05 HE
|
Fractyl Health, Inc.
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
Gift of Life Marrow Registry Names Dr. Yen-Michael Hsu as Co-Chief Medical Officer
13 août 2024 11h47 HE
|
Gift of Life Marrow Registry
BOCA RATON, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gift of Life Marrow Registry today announced the appointment of Yen-Michael Hsu, M.D., Ph.D., MBA, CABP as Co-Chief Medical Officer. Dr. Hsu's...
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
08 août 2024 06h45 HE
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trialOCU410 preliminary safety and efficacy data expected later this year Expanded...
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
05 août 2024 06h30 HE
|
Ocugen
MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
02 août 2024 15h22 HE
|
Ocugen
MALVERN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
01 août 2024 07h05 HE
|
uniQure Inc.
~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of...
CRISPR and Cas Gene Global Research Report 2024 | Now Available
01 août 2024 06h10 HE
|
Research and Markets
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Gene Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The crispr and cas gene market size has...
Gene Therapy in Rare Diseases Therapeutics Pipeline Report 2024: Analytical Perspective, Current Treatment Patterns, Collaborations, Licensing, Acquisitions
01 août 2024 04h02 HE
|
Research and Markets
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Gene therapy in Rare Diseases - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.Gene therapy in Rare...
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
31 juil. 2024 21h15 HE
|
Ocugen
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
31 juil. 2024 16h15 HE
|
Ocugen
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...